2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3563 Historical long-term comparison of cladribine-rituximab with purine analog monotherapy shows marked improvement in progression-free and relapse-free survival, in addition to survival without minimal residual disease.

Yoonhee Choi, M.D., Laura McDonald2, Constance Yuan, MD, PhD3, Hao-Wei Wang, MD, PhD4, Dana Delgado Colon, MD5, Evgeny Arons, PhD6, Hong Zhou, MS7, Mark Raffeld, MD8, Liqiang Xi, MD9, Julie Feurtado, RN10, Lacey James, CRNP11, Katherine R Calvo, MD, PhD12, Irina Maric, MD13, Sunil Iyengar, PhD14, Claire Dearden, MBBS, MD15, Dima El-Sharkawi, PhD, MBBS, FRCPath, MA, MRCP16, Robert J Kreitman, MD17
1 National Institute of Health, Bethesda, Maryland, United States
2 Royal Marsden Hospital NHS Trust, London, United Kingdom
3 National Institute of Health, Bethesda, Maryland, United States
4 National Institute of Health, Bethesda, Maryland, United States
5 National Institute of Health, Bethesda, Maryland, United States
6 National Institute of Health, Bethesda, Maryland, United States
7 National Institute of Health, Bethesda, Maryland, United States
8 National Institute of Health, Bethesda, Maryland, United States
9 National Institute of Health, Bethesda, Maryland, United States
10 National Institute of Health, Bethesda, Maryland, United States
11 National Institute of Health, Bethesda, Maryland, United States
12 National Institute of Health, Bethesda, Maryland, United States
13 National Institute of Health, Bethesda, Maryland, United States
14 Royal Marsden Hospital NHS Trust, London, United Kingdom
15 Royal Marsden Hospital NHS Trust, London, United Kingdom
16 Royal Marsden Hospital NHS Trust, London, United Kingdom
17 National Institute of Health, Bethesda, Maryland, United States

Background: Hairy cell leukemia (HCL) is a B-cell malignancy driven by the BRAF V600E mutation and is highly responsive to first-line treatment with purine analogs cladribine or pentostatin. Prior long-term series, including the Royal Marsden Hospital (RMH) experience, found no significant difference in outcome between the two agents, with median relapse-free survival of ~16 years but relapse in 30-40% of patients, reflecting persistent minimal residual disease (MRD). First-line cladribine followed by 8 weekly doses of rituximab begun 4 weeks later (CDA+R) increases the CR rate from ~80% to ~100% and the MRD-free rate by 3-4 months was reported to be 78%. At NIH, a randomized first-line trial of cladribine with 8 weekly doses of rituximab begun day 1 of cladribine (CDAR) achieved MRD-free CR rate of 97% by 6 months vs 24% for cladribine alone (p<0.0001). Synergy, previously reported ex vivo by rituximab increasing cell-sensitivity of cladribine, would be provided by CDAR but not by regimens delaying rituximab until after cladribine exits. In a preliminary report, a 25-patient validation CDAR cohort added to the 34-patient CDAR randomized arm resulted in an MRD-free CR rate of 92% at 6 months which was slightly higher than the historical 78% MRD-free CR rate from CDA+R at 3-4 months (p=0.032). However, purine analog monotherapy and CDAR have never been compared even historically for long-term endpoints more relevant than CR or MRD-free CR, such as progression-free, relapse-free, and overall survival (PFS, RFS, and OS, respectively). Using long-term follow-up data from RMH and NIH, we performed such a comparison to define whether the choice of purine analog, or the addition of concurrent rituximab, drives long-term outcome.

Patients and Methods: The RMH cohort included 91 patients who received first-line cladribine (n=53) or pentostatin (n=38). OS (event=death), PFS (event=relapse or death), and RFS (event=hematologic relapse or death) were measured from treatment start, determined by Kaplan-Meier, and compared by log-rank test and multivariable Cox regression. Second malignancies and cause of death were recorded.

Results: First line purine-analog monotherapy from RMH (n=91) was compared with CDAR from NIH (n=59). Follow-up was 0.2–33.2 years (median 15.7 years) for cladribine, 0.1–39.6 (median 24.9) years for pentostatin, 0.1–39.6 (median 20.3) years for both, and 5.0–16.9 (median 12.5) years for CDAR. Cladribine vs pentostatin monotherapy showed no significant difference in OS at 10 years (89% vs 89%, p=0.66), PFS (median 72 vs 120 months,p=0.46), or RFS (median 72 vs 121 months, p=0.36). Equivalence was robust on multivariable adjustment, with age the only significant prognostic factor for OS (adjusted hazard ratio 1.82, 95% confidence interval 1.28–2.59, p=0.0008). Second malignancies occurred in 31% of patients and were identical between arms (28% vs 34%). Of 25 deaths after cladribine or pentostatin, only 6 (24%) were HCL-related; most patients died of unrelated causes, indicating patients usually die with, not of, HCL. First-line CDAR was associated with markedly superior relapse outcomes vs purine-analog monotherapy, with respective 10-year PFS 98% vs 45% and RFS 98% vs 46% (log-rank p<1x10-12 for both). OS did not yet reach a trend (10-year 97% vs 89%; p=0.13). Notably, CR to purine-analog monotherapy lasted a median 120 months with only 50% maintained at 10 years, whereas with CDAR both CR and MRD-free CR were 98%-maintained at 10-years. Thus, CDAR induces deep MRD-free CRs with lower risk of progression and clinical relapse compared to purine analog monotherapy.

Conclusion: Cladribine vs pentostatin are truly equivalent long term as first-line therapy for HCL, with no difference in relevant endpoints. Adding concurrent rituximab on day 1 of cladribine (CDAR) leads to deep, MRD-free CRs that translate into markedly superior PFS and RFS without an OS difference. Events limiting PFS and RFS were progressions/relapses not just in the bone marrow, but also in cytopenias which would require additional treatment. Limitations include the retrospective cross-cohort design and, for the CDAR arm, shorter (though mature, median ~12.5-year) follow-up with few relapse events. Longer follow-up and additional data may determine if there is an OS difference between purine analog monotherapy and CDAR, or if there are PFS and RFS differences between CDAR and either CDA+R or rituximab added at other time points after cladribine.

Yoonhee Choi, M.D.: No relevant conflicts of interest to declare.